Resveratrol potentiates the in vitro and in vivo anti-tumoral effects of curcumin in head and neck carcinomas

Oncotarget

Volumn 5, Issue 21, 2014, Pages 10745-10762

  Masuelli, Laura ^a   Di Stefano, Enrica ^a   Fantini, Massimo ^b   Mattera, Rosanna ^a   Benvenuto, Monica ^b   Marzocchella, Laura ^b   Sacchetti, Pamela ^a   Focaccetti, Chiara ^b   Bernardini, Roberta ^b   Tresoldi, Ilaria ^b   Izzi, Valerio ^b   Mattei, Maurizio ^b   Frajese, Giovanni Vanni ^c   Lista, Florigio ^d   Modesti, Andrea ^b   Bei, Roberto ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c Universitá di Roma   (Italy)

^d Ctro Studi Ric Sanita V Esercito   (Italy)

Author keywords

Curcumin; Head and neck cancer; Polyphenols; Resveratrol

Indexed keywords

CURCUMIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN BAX; PROTEIN BCL 2; PROTEIN LC3 II; REACTIVE OXYGEN METABOLITE; RESVERATROL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; STILBENE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; BAGG ALBINO MOUSE; CANCER CELL; CANCER INHIBITION; CARCINOMA CELL LINE; CELL VACUOLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; ENZYME PHOSPHORYLATION; FLUORESCENCE ACTIVATED CELL SORTING; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IC50; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SALIVARY GLAND CANCER; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING; ANIMAL; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; FLUORESCENT ANTIBODY TECHNIQUE; HEAD AND NECK NEOPLASMS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SALIVARY GLAND NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; CURCUMIN; DRUG SYNERGISM; FLUORESCENT ANTIBODY TECHNIQUE; HEAD AND NECK NEOPLASMS; HUMANS; IN VITRO TECHNIQUES; MICE; MICE, INBRED BALB C; PHOSPHORYLATION; REACTIVE OXYGEN SPECIES; SALIVARY GLAND NEOPLASMS; SIGNAL TRANSDUCTION; STILBENES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84916938355     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2534     Document Type: Article

References (66)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin. 1999; 49: 8-31.
2. Braakhuis BJ, Leemans CR, BrakenhoffRH. A genetic progression model of oral cancer: current evidence and clinical implications. J Oral Pathol Med. 2004; 33: 317-322.
3. Tsao R. Chemistry and biochemistry of dietary polyphenols. Nutrients. 2010; 2: 1231-1246.
4. Benvenuto M, Fantini M, Masuelli L, De Smaele E, Zazzeroni F, Tresoldi I, Calabrese G, Galvano F, Modesti A, Bei R. Inhibition of ErbB receptors, Hedgehog and NFkappaB signaling by polyphenols in cancer. Front Biosci (Landmark Ed). 2013; 18: 1290-1310.
5. Marzocchella L, Fantini M, Benvenuto M, Masuelli L, Tresoldi I, Modesti A, Bei R. Dietary flavonoids: molecular mechanisms of action as anti- inflammatory agents. Recent Pat Inflamm Allergy Drug Discov. 2011; 5: 200-220.
6. Iriti M, Varoni EM. Chemopreventive potential of flavonoids in oral squamous cell carcinoma in human studies. Nutrients. 2013; 5: 2564-2576.
7. Prasad S, Tyagi AK, Aggarwal BB. Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice. Cancer Res Treat. 2014; 46: 2-18.
8. Shureiqi I, Baron JA. Curcumin chemoprevention: the long road to clinical translation. Cancer Prev Res (Phila). 2011; 4: 296-298.
9. Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett. 2008; 269: 199-225.
10. Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB. Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett. 2008; 267: 133-164.
11. Bar-Sela G, Epelbaum R, Schaffer M. Curcumin as an anticancer agent: review of the gap between basic and clinical applications. Curr Med Chem. 2010; 17: 190-197.
12. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, Pirmohamed M, Gescher AJ, Steward WP. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res. 2004; 10: 6847-6854.
13. Bishayee A. Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev Res (Phila). 2009; 2: 409-418.
14. Goswami SK, Das DK. Resveratrol and chemoprevention. Cancer Lett. 2009; 284: 1-6.
15. Kundu JK, Surh YJ. Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives. Cancer Lett. 2008; 269: 243-261.
16. Kapetanovic IM, Muzzio M, Huang Z, Thompson TN, McCormick DL. Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother Pharmacol. 2011; 68: 593-601.
17. Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos. 2004; 32: 1377-1382.
18. Zlotogorski A, Dayan A, Dayan D, Chaushu G, Salo T, Vered M. Nutraceuticals as new treatment approaches for oral cancer: II. Green tea extracts and resveratrol. Oral Oncol. 2013; 49: 502-506.
19. ElAttar TM, Virji AS. Modulating effect of resveratrol and quercetin on oral cancer cell growth and proliferation. Anticancer Drugs. 1999; 10: 187-193.
20. Chang PY, Peng SF, Lee CY, Lu CC, Tsai SC, Shieh TM, Wu TS, Tu MG, Chen MY, Yang JS. Curcumin-loaded nanoparticles induce apoptotic cell death through regulation of the function of MDR1 and reactive oxygen species in cisplatin-resistant CAR human oral cancer cells. Int J Oncol. 2013; 43: 1141-1150.
21. Kim JY, Cho TJ, Woo BH, Choi KU, Lee CH, Ryu MH, Park HR. Curcumin-induced autophagy contributes to the decreased survival of oral cancer cells. Arch Oral Biol. 2012; 57: 1018-1125.
22. Ip SW, Wu SY, Yu CC, Kuo CL, Yu CS, Yang JS, Lin ZP, Chiou SM, Chung HK, Ho HC, Chung JG. Induction of apoptotic death by curcumin in human tongue squamous cell carcinoma SCC-4 cells is mediated through endoplasmic reticulum stress and mitochondria-dependent pathways. Cell Biochem Funct. 2011; 29: 641-650.
23. Liao S, Xia J, Chen Z, Zhang S, Ahmad A, Miele L, Sarkar FH, Wang Z. Inhibitory effect of curcumin on oral carcinoma CAL-27 cells via suppression of Notch-1 and NF-κB signaling pathways. J Cell Biochem. 2011; 112: 1055-1065.
24. Chakravarti N, Kadara H, Yoon DJ, Shay JW, Myers JN, Lotan D, Sonenberg N, Lotan R. Differential inhibition of protein translation machinery by curcumin in normal, immortalized, and malignant oral epithelial cells. Cancer Prev Res (Phila). 2010; 3: 331-338.
25. Chakravarti N, Myers JN, Aggarwal BB. Targeting constitutive and interleukin-6-inducible signal transducers and activators of transcription 3 pathway in head and neck squamous cell carcinoma cells by curcumin (diferuloylmethane). Int J Cancer. 2006; 119: 1268-1275.
26. Masuelli L, Marzocchella L, Focaccetti C, Tresoldi I, Palumbo C, Izzi V, Benvenuto M, Fantini M, Lista F, Tarantino U, Modesti A, Galvano F, Bei R. Resveratrol and diallyl disulfide enhance curcumin-induced sarcoma cell apoptosis. Front Biosci (Landmark Ed). 2012; 17: 498-508.
27. Eicheler W, Zips D, Dörfler A, Grénman R, Baumann M. Splicing mutations in TP53 in human squamous cell carcinoma lines influence immunohistochemical detection. J Histochem Cytochem. 2002; 50: 197-204.
28. D'Amato V, Rosa R, D'Amato C, Formisano L, Marciano R, Nappi L, Raimondo L, Di Mauro C, Servetto A, Fusciello C, Veneziani BM, De Placido S, Bianco R. The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models. Br J Cancer. 2014; 110: 2887-2995.
29. Caicedo-Granados EE, Wuertz BR, Marker PH, Lee GS, Ondrey FG. The effect of indomethacin on paclitaxel sensitivity and apoptosis in oral squamous carcinoma cells: the role of nuclear factor-κB inhibition. Arch Otolaryngol Head Neck Surg. 2011; 137: 799-805.
30. Allen CT, Ricker JL, Chen Z, Van Waes C. Role of activated nuclear factor-kappaB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck. Head Neck. 2007; 29: 959-971.
31. Vander Broek R, Snow GE, Chen Z, Van Waes C. Chemoprevention of head and neck squamous cell carcinoma through inhibition of NF-κB signaling. Oral Oncol. 2011; S1368-8375: 00714-00718.
32. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, Kominami E, Ohsumi Y, Yoshimori T. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 2000; 19: 5720-5728.
33. Barth S, Glick D, Macleod KF. Autophagy: assays and artifacts. J Pathol. 2010; 221: 117-124.
34. Masuelli L, Fantini M, Benvenuto M, Sacchetti P, Giganti MG, Tresoldi I, Lido P, Lista F, Cavallo F, Nanni P, Schlom J, Modesti A, Bei R. Intratumoral delivery of recombinant vaccinia virus encoding for ErbB2/Neu inhibits the growth of salivary gland carcinoma cells. J Transl Med. 2014; 12:122.
35. Ding Y, Yao H, Yao Y, Fai LY, Zhang Z. Protection of dietary polyphenols against oral cancer. Nutrients. 2013; 5: 2173-2191.
36. De Stefani E, Ronco A, Mendilaharsu M, and Deneo-Pellegrini H. Diet and risk of cancer of the upper aerodigestive tract-II. Oral Oncol. 1999; 35: 22-26.
37. Rossi M, Garavello W, Talamini R, Negri E, Bosetti C, Dal Maso L, Lagiou P, Tavani A, Polesel J, Barzan L, Ramazzotti V, Franceschi S, La Vecchia C. Flavonoids and the risk of oral and pharyngeal cancer: a case-control study from Italy. Cancer Epidemiol Biomarkers Prev. 2007; 16: 1621-1625.
38. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, JeeSH, Chen GS et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or premalignant lesions. Anticancer Res. 2001; 21: 2895-2900.
39. Park W, Amin AR, Chen ZG, Shin DM. New perspectives of curcumin in cancer prevention. Cancer Prev Res (Phila). 2013; 6: 387-400.
40. Bush JA, Cheung KJ Jr, Li G. Curcumin induces apoptosis in human melanoma cells through a Fas receptor/caspase-8 pathway independent of p53. Exp Cell Res. 2001; 271: 305-314.
41. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol. 2006; 71: 1397-421.
42. Jee SH, Shen SC, Tseng CR, Chiu HC, Kuo ML. Curcumin induces a p53-dependent apoptosis in human basal cell carcinoma cells. J Invest Dermatol. 1998; 111: 656-661.
43. Jiang MC, Yang-Yen HF, Yen JJ, Lin JK. Curcumin induces apoptosis in immortalized NIH 3T3 and malignant cancer cell lines. Nutr Cancer. 1996; 26: 111-120.
44. Han SS, Chung ST, Robertson DA, Ranjan D, Bondada S. Curcumin causes the growth arrest and apoptosis of B cell lymphoma by downregulation of egr-1, c-myc, bcl-XL, NFkappa B, and p53. Clin Immunol. 1999; 93: 152-161.
45. Moos PJ, Edes K, Mullally JE, Fitzpatrick FA. Curcumin impairs tumor suppressor p53 function in colon cancer cells. Carcinogenesis. 2004; 25: 1611-1617.
46. Tsvetkov P, Asher G, Reiss V, Shaul Y, Sachs L, Lotem J. Inhibition of NAD(P)H:quinone oxidoreductase 1 activity and induction of p53 degradation by the natural phenolic compound curcumin. Proc Natl Acad Sci USA. 2005; 102: 5535-5540.
47. Cornel A, Sorrentino G, Capaci V, Del Sal G. The cytoplasmic side og p53's oncosuppressive activities. FEBS Lett. 2014; 588: 2600-2609.
48. Masuelli L, Marzocchella L, Quaranta A, Palumbo C, Pompa G, Izzi V, Canini A, Modesti A, Galvano F, Bei R. Apigenin induces apoptosis and impairs head and neck carcinomas EGFR/ErbB2 signaling. Front Biosci (Landmark Ed). 2011; 16: 1060-1068.
49. Masuelli L, Budillon A, Marzocchella L, Mrozek MA, Vitolo D, Di Gennaro E, Losito S, Sale P, Longo F, Ionna F, Lista F, Muraro R, Modesti A et al. Caveolin-1 overexpression is associated with simultaneous abnormal expression of the E-cadherin/α-β catenins complex and multiple ErbB receptors and with lymph nodes metastasis in head and neck squamous cell carcinomas. J Cell Physiol. 2012; 227: 3344-3353.
50. Bei R, Pompa G, Vitolo D, Moriconi E, Ciocci L, Quaranta M, Frati L, Kraus MH, Muraro R. Co-localization of multiple ErbB receptors in stratified epithelium of oral squamous cell carcinoma. J Pathol. 2001; 195: 343-348.
51. Majumdar AP, Banerjee S, Nautiyal J, Patel BB, Patel V, Du J, Yu Y, Elliott AA, Levi E, Sarkar FH. Curcumin synergizes with resveratrol to inhibit colon cancer. NutrCancer. 2009; 61: 544-553.
52. Cagnol S, Chambard JC. ERK and cell death: mechanisms of ERK-induced cell death-apoptosis, autophagy and senescence. FEBS J. 2010; 277: 2-21.
53. Ravi R, Bedi A, Fuchs EJ, Bedi A. CD95 (Fas)-induced caspase-mediated proteolysis of NF-kappaB. Cancer Res. 1998; 58: 882-886.
54. Kang KH, Lee KH, Kim MY, Choi KH. Caspase-3-mediated cleavage of the NF-kappa B subunit p65 at the NH2 terminus potentiates naphthoquinone analog-induced apoptosis. J Biol Chem. 2001; 276: 24638-24644.
55. Berghe WV, Plaisance S, Boone E, De Bosscher K, Schmitz ML, Fiers W, Haegeman G. p38 and extracellular signalregulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-kB p65 transactivation mediated by tumor necrosis factor. J Biol Chem. 1998; 273: 3285-3290.
56. Bui NT, Livolsi A, Peyron JF, Prehn JH. Activation of nuclear factor kappaB and Bcl-x survival gene expression by nerve growth factor requires tyrosine phosphorylation of IkappaBalpha. J Cell Biol. 2001; 152: 753-764.
57. Kang R, Zeh HJ, Lotze MT, Tang D. The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ. 2011; 18: 571-580.
58. Shinojima N, Yokoyama T, Kondo Y, Kondo S. Roles of the Akt/mTOR/p70S6K and ERK1/2 signaling pathways in curcumin-induced autophagy. Autophagy. 2007; 3: 635-637.
59. Woo JH, Kim YH, Choi YJ, Kim DG, Lee KS, Bae JH, Min DS, Chang JS, Jeong YJ, Lee YH, Park JW, Kwon TK. Molecular mechanisms of curcumin-induced cytotoxicity: induction of apoptosis through generation of reactive oxygen species, down-regulation of Bcl-XL and IAP, the release of cytochrome c and inhibition of Akt. Carcinogenesis. 2003; 24: 1199-1208.
60. Ettl T, Schwarz-Furlan S, Gosau M, Reichert TE. Salivary gland carcinomas. Oral Maxillofac Surg 2012; 16: 267-283.
61. Pannellini T, Spadaro M, Di Carlo E, Ambrosino E, Iezzi M, Amici A, Lollini PL, Forni G, Cavallo F, Musiani P. Timely DNA vaccine combined with systemic IL-12 prevents parotid carcinomas before a dominant-negative p53 makes their growth independent of HER-2/neu expression. J Immunol. 2006; 176: 7695-7703.
62. Masuelli L, Benvenuto M, Fantini M, Marzocchella L, Sacchetti P, Di Stefano E, Tresoldi I, Izzi V, Bernardini R, Palumbo C, Mattei M, Lista F, Galvano F et al. Curcumin induces apoptosis in breast cancer cell lines and delays the growth of mammary tumors in neu transgenic mice. J Biol Regul Homeost Agents. 2013; 27: 105-119.
63. Masuelli L, Marzocchella L, Focaccetti C, Lista F, Nardi A, Scardino A, Mattei M, Turriziani M, Modesti M, Forni G, Schlom J, Modesti A, Bei R. Local delivery of recombinant vaccinia virus encoding for neu counteracts growth of mammary tumors more efficiently than systemic delivery inneu transgenic mice. Cancer Immunol Immunother. 2010; 59: 1247-1258.
64. Elmann A, Mordechay S, Erlank H, Telerman A, Rindner M, Ofir R. Anti-neuroinflammatory effects of the extract of Achillea fragrantissima. BMC Complement Altern Med. 2011; 11:98.
65. Masuelli L, Focaccetti C, Cereda V, Lista F, Vitolo D, Trono P, Gallo P, Amici A, Monaci P, Mattei M, Modesti M, Forni G, Kraus MH, Muraro R, Modesti A, Bei R. Genespecific inhibition of breast carcinoma in BALB-neuT mice by active immunization with rat Neu or human ErbB receptors. Int J Oncol. 2007; 30: 381-392.
66. Bei R, Guptill V, Masuelli L, Kashmiri SV, Muraro R, Frati L, Schlom J, Kantor J. The use of a cationic liposome formulation (DOTAP) mixed with a recombinant tumorassociated antigen to induce immune responses and protective immunity in mice. J Immunother. 1998; 21: 159-169.